BLCO

Business Context and Reporting Period

Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A global eye health company operating in three segments: Vision Care (contact lenses, OTC eye drops, vitamins), Pharmaceuticals (prescription eye medications), and Surgical (medical devices, IOLs, surgical systems). The company is currently a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 88% of outstanding shares. A full separation from BHC is planned but remains subject to conditions, including debt leverage ratios and regulatory approvals.

Key Financial Metrics (2025 vs. 2024)

Note: Free Cash Flow calculated as Operating Cash Flow less Purchases of Property, Plant, and Equipment ($349M in 2025).

Material Changes and Segment Performance

• Revenue Growth: Driven by increased volumes ($301M), favorable foreign currency impacts ($58M), and acquisitions ($16M). Growth was partially offset by decreased net realized pricing ($53M) and product discontinuations ($12M).
• Segment Results:
  • Vision Care: Revenue $2,923M (+7%). Profit $849M (+5%). Driven by dry eye portfolio (Lumify, PreserVision) and contact lens sales.
  • Pharmaceuticals: Revenue $1,284M (+6%). Profit $258M (+1%). Growth driven by MIEBO and international sales, offset by pricing pressures on XIIDRA and MIEBO.
  • Surgical: Revenue $894M (+6%). Profit $18M (-59%). Significant profit decline attributed to the voluntary recall of enVista IOL products and higher selling expenses.
• Cost Pressures: Cost of Goods Sold increased 9% due to higher volumes, manufacturing variances (including tariffs and recall reserves), and royalties. SG&A increased 7% due to higher selling costs and share-based compensation.

Guidance, Outlook, and Risks

• Separation from BHC: The company remains a controlled company. The separation (via Distribution or Sale Transaction) is contingent on BHC achieving targeted debt leverage ratios and obtaining necessary approvals. There is no assurance the separation will occur on the anticipated timeline.
• Product Pipeline & Launches:
  • Lumify Luxe: NDA submission anticipated in H1 2026.
  • enVista Beyond (EDOF): U.S. launch anticipated in 2027.
  • ELIOS: U.S. submission anticipated in H1 2026.
• Key Risks:
  • Recall Impact: A voluntary recall of enVista IOLs in Q1 2025 due to raw material issues impacted Surgical segment profitability, though sales recovered to pre-recall levels by Q4 2025.
  • Debt Covenants: The company carries significant debt ($5.1B principal). The Revolving Credit Facility contains a financial covenant requiring a maximum first lien net leverage ratio (starting at 5.75:1.00) if borrowings exceed 35% of commitments.
  • Geopolitical & Trade: Exposure to tariffs, the Russia-Ukraine conflict (approx. 3% of revenue), and Middle East tensions. The company is monitoring the impact of the "One Big Beautiful Bill Act" on tax provisions.
  • Patent Expirations: Risks associated with generic competition for key products like PreserVision and Lumify, though the company is actively litigating to defend exclusivity.

Investor Verification Checklist

• Debt Leverage Ratios: Verify if BHC has met the targeted debt leverage ratios required to trigger the Distribution/Separation.
• enVista Recall Resolution: Confirm that the raw material supply chain issues for enVista IOLs are fully resolved and no further quality incidents are pending.
• Rebate Reserves: Review the adequacy of the $556M product rebate reserve (including Medicaid), which is a critical accounting estimate subject to significant judgment.
• Separation Timeline: Monitor for updates on the "Distribution Arrangement Agreement" and any potential termination by BHC.
• Generic Competition: Track the status of Paragraph IV litigation regarding Lumify, Vyzulta, and Lotemax SM, as settlements could impact future revenue streams.